<DOC>
	<DOC>NCT01772368</DOC>
	<brief_summary>The primary objective of this study is to evaluate the dose response, efficacy, and safety of 4 different doses of salmeterol Spiromax (6.25, 12.5, 25, and 50 mcg) each combined with a fixed dose of fluticasone propionate (100 mcg) delivered as Fluticasone/Salmeterol Spiromax® Inhalation Powder (FS Spiromax) when administered as a single dose in subjects 12 years of age and older with persistent asthma.</brief_summary>
	<brief_title>Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Written informed consent/assent General good health Diagnosis of asthma as defined by the National Institutes of Health (NIH) A best FEV1 of 40%85% of the predicted normal value during the screening visit (SV) Subjects need to demonstrate a ≥ 15% reversibility of FEV1 within 30 minutes following 4 inhalations of albuterol inhalation aerosol (if required, spacers are permitted for reversibility testing) at the SV. Other inclusion criteria apply History of lifethreatening asthma that is defined for this protocol as an asthma episode that required intubation. Culturedocumented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus, or middle ear that is not resolved within 2 weeks prior to the SV. Any asthma exacerbation requiring oral corticosteroids within 3 months of the SV. A subject must not have had any hospitalization for asthma within 6 months prior to the SV. Taking longacting βagonists within 2 weeks of the SV Other exclusion criteria apply.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Asthma</keyword>
	<keyword>dry powder inhaler</keyword>
	<keyword>long-acting beta2-agonist</keyword>
	<keyword>bronchodilation</keyword>
	<keyword>bronchodilator</keyword>
	<keyword>metered dose inhaler</keyword>
	<keyword>inhaled corticosteroid</keyword>
</DOC>